Contract vaccine maker IDT Biologika will bulk up its North American product pipeline when a second Canadian plant comes online, possibly as early as next summer.<\/p>\n
The German company on Aug. 21 announced the purchase of a 32,000-square foot building in Cambridge, Ontario. The location, west of Toronto, is inside an area known as Canada\u2019s Technology Triangle.<\/p>\n
An IDT subsidiary, Gallant Custom Laboratories, produces autogenous veterinary biologics at another plant in Cambridge. Autogenous biologics are customized vaccines used by veterinarians when commercial vaccines are not available to treat livestock, the company noted.<\/p>\n
\u201cWe intend to raise the bar for manufacturing technology and innovation, capacity and development of veterinary biologics in Canada,\u201d said Andreas Kastenbauer, IDT\u2019s managing director and head of the company\u2019s global Animal Health Division.<\/p>\n
\u201cAs we continue to expand our footprint across the Americas, veterinarians, farmers and government agencies in Canada and in the region are sure to reap important benefits from the breadth and depth of our capabilities that will emanate from this vaccine manufacturing hub in the years to come,\u201d he said.<\/p>\n","protected":false},"excerpt":{"rendered":"
Contract vaccine maker IDT Biologika will bulk up its North American product pipeline when a second Canadian plant comes online, possibly as early as next summer.<\/p>\n","protected":false},"author":45,"featured_media":833,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"iawp_total_views":0,"footnotes":""},"categories":[90],"tags":[],"class_list":["post-832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-online","clinical_topics-news"],"acf":{"hide_sidebar":false,"hide_sidebar_ad":false,"hide_all_ads":false},"yoast_head":"\n